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Background: The ABC-02 (Advanced Biliary Tract Cancer) study established cisplatin and gemcitabine (CisGem) as the standard
first-line chemotherapy for patients with locally advanced or metastatic biliary tract cancer (BTC). We examine quality of life (QoL),
describe the long-term survivors and provide a long-term outcome.
Methods: A total of 410 BTC patients were randomised to receive either CisGem or gemcitabine alone (Gem); 324 patients
consented to complete EORTC QLQ-C30 and EORTC QLQ-PAN26 QoL questionnaires; 268 (83%) patients returned at least one
QoL questionnaire (134 in each arm). Long-term survivors were defined as those surviving over 2 years and we performed a final
analysis of the primary outcome; overall survival (OS).
Results: Most QoL scales showed a trend favouring the combined CisGem arm, including functional and symptomatic scales,
although the differences were not statistically significant. Forty-five (11%)) patients survived at least 2 years (34 received CisGem and
11 Gem) and 21 (5%) 3 years or more (14 received CisGem and 7 Gem). After a median follow-up of 9.2 months and 398 deaths, the
median OS was 11.7 months for CisGem and 8.1 months for Gem (hazard ratio (HR)¼ 0.65, 95% CI: 0.53–0.79, Po0.001).
Conclusions: The survival advantage of CisGem compared to Gem was not associated with an improvement or deterioration of
QoL. Long-term survivors were more likely to have received CisGem and the long-term OS is identical to that previously
described.
Biliary tract cancers (including cholangiocarcinoma and cancers of
the gallbladder and ampulla of Vater, BTC) are uncommon cancers
with a poor prognosis (de Groen et al, 1999). The standard of care
for advanced biliary tract cancers (ABC) was established following
publication of the ABC-02 (Advanced Biliary Tract Cancer) trial,
which demonstrated that the addition of cisplatin to gemcitabine
(CisGem vs Gem) significantly improved overall survival (OS) and
progression-free survival by 3.6 months and 3 months, respectively
compared to gem alone (Valle et al, 2010). These data were
supported by a similar Japanese phase 2 study (Okusaka et al,
2010) and a subsequent meta-analysis of these data with ABC-02
(Valle et al, 2013).
Maintaining quality of life is a key goal of treatment and impacts
on the decision patients make with respect to treatment.
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Of particular concern for the ABC-02 study was the potential
impact of cisplatin-related fatigue, which numerically increased in
the ABC-01 study, the randomised phase 2 study that preceded
ABC-02 (Valle et al, 2009). Additionally, we wished to document
the global impact that any change in episodes of biliary sepsis, a
difficult and common problem in BTCs, may have had.
We report quality of life in the ABC-02 study. Additionally we
were interested in factors that defined long-term survivors, as we
noted that, unlike historical data and clinical experience, there were
a number of long-term survivors. We took the opportunity to re-
analyse the primary outcome of the ABC-02 study; OS.
METHODS AND METHODS
Patients. A total of 324 patients asked to complete quality of life
(QoL) questionnaires as part of the ABC-02 study. The 86 patients
enrolled in the ABC-01 study who contributed to the efficacy
outcome of the combined ABC-01 and ABC-02 cohort did not
complete QoL as this was not part of the randomised phase 2
protocol. Patients had a histopathological or cytological diagnosis
of non-resectable, recurrent or metastatic biliary tract carcinoma
(intra- or extra-hepatic cholangiocarcinoma), gallbladder or
ampullary carcinoma; were aged X18 years; had an estimated life
expectancy 43 months; ECOG performance status 0–2; and
adequate haematological, renal and liver function.
Treatment. Patients were treated as described previously (Valle
et al, 2010). Supportive medications such as anti-emetics were not
proscribed and were given at the investigators discretion.
Quality of life. All patients were asked to complete the self-
completion EORTC Quality of Life Questionnaire-Cancer 30
(EORTC QLQ-C30; Aaronson et al, 1993) and EORTC Quality of
Life Questionnaire-Pancreatic Cancer 26 (EORTC QLQ-PAN26;
Fitzsimmons et al, 1999), though this was optional. Quality of life
was assessed at baseline, 12 weeks into treatment, one month after
the completion of treatment, and 3 and 6months after the 1month
assessment.
Statistical methods. We used the Pearson w2 test and a non-
parametric test for trend across ordered groups to assess each
baseline characteristic (sex, age, disease status, primary site,
histology, ECOG performance status and prior therapy) and
treatment for any difference and trend over survival time,
respectively. We categorised age into three age groups (23–60,
60–70 and 70–84 years), maintaining a large number of patients in
each group and using clinically meaningful age boundaries. We
used Kaplan-Meier curves and Cox proportional hazards regres-
sion to estimate survival and the hazard ratio (HR) for OS among
all patients.
The association between baseline QoL responses and OS was
done by categorising the QoL responses (initially on the 0–100
continuous scale) into low scores (p50 score) or high scores (450
Table 1. Cox regression analysis for the association between each QoL response at baseline and overall survival
QoL scoresb
Overall survival univariate
cox modelsc
Overall survival multivariate
cox modelsc,d
QoL responsea
p50 score
N (%)e
450 score
N (%)
HR (99% CI) 450 score
vs p50 score P-value
HR (99% CI) 450 score
vs p50 score P-value
Global health 98 (30%) 157 (48%) 0.59 (0.42–0.83) o0.001 0.63 (0.44–0.91) 0.001
Social functioning 78 (24%) 176 (54%) 0.78 (0.55–1.12) 0.08 0.93 (0.62–1.40) 0.64
Emotional functioning 61 (19%) 195 (60%) 0.87 (0.59–1.27) 0.34 0.91 (0.60–1.38) 0.57
Cognitive functioning 39 (12%) 217 (67%) 0.86 (0.54–1.35) 0.39 0.93 (0.57–1.52) 0.72
Role functioning 97 (30%) 160 (49%) 0.67 (0.48–0.94) 0.002 0.77 (0.53–1.11) 0.06
Physical functioning 46 (14%) 213 (66%) 0.46 (0.30–0.70) o0.001 0.56 (0.34–0.92) 0.003
Appetite loss 192 (59%) 65 (20%) 1.60 (1.10–2.34) 0.001 1.42 (0.96–2.10) 0.02
Financial difficulties 210 (65%) 44 (14%) 0.90 (0.58–1.39) 0.54 0.91 (0.57–1.45) 0.59
Nausea and vomiting 244 (75%) 15 (5%) 1.89 (0.93–3.86) 0.02 1.98 (0.94–4.17) 0.02
Pain 200 (62%) 59 (18%) 1.70 (1.15–2.53) o0.001 1.50 (0.94–2.38) 0.02
Insomnia 180 (56%) 79 (24%) 1.21 (0.85–1.73) 0.16 1.27 (0.85–1.87) 0.12
Fatigue 177 (55%) 82 (25%) 1.49 (1.05–2.12) 0.003 1.39 (0.92–2.10) 0.04
Constipation 217 (67%) 38 (12%) 1.40 (0.88–2.23) 0.06 1.24 (0.71–2.14) 0.32
Diarrhoea 236 (73%) 17 (5%) 0.95 (0.50–1.82) 0.84 0.94 (0.48–1.84) 0.80
Dyspnoea 231 (71%) 27 (8%) 1.21 (0.71–2.08) 0.36 1.23 (0.70–2.14) 0.34
Satisfaction with health care 48 (15%) 204 (63%) 1.15 (0.75–1.76) 0.40 1.15 (0.74–1.80) 0.41
Sexual functioning 102 (31%) 114 (35%) 0.67 (0.47–0.96) 0.005 0.69 (0.46–1.02) 0.01
Digestive symptoms 213 (66%) 43 (13%) 1.67 (1.08–2.59) 0.003 1.42 (0.90–2.25) 0.05
Hepatic 245 (76%) 11 (3%) 1.30 (0.58–2.90) 0.40 1.07 (0.46–2.47) 0.84
Pancreatic pain 199 (61%) 58 (18%) 1.51 (1.02–2.25) 0.007 1.39 (0.90–2.15) 0.05
Body image 220 (68%) 35 (11%) 1.14 (0.71–1.82) 0.48 1.05 (0.65–1.72) 0.78
Altered bowel habit 226 (70%) 29 (9%) 1.05 (0.63–1.75) 0.80 1.04 (0.61–1.77) 0.85
aScores range from 0–100 for all endpoints. For the global health and functional scales (including satisfaction with health care and sexual functioning) 0 indicates poor health and 100 good
health. For all other scales, 0 indicates no symptoms and 100 high level of symptoms.
bQuality of life forms were only requested from the 324 ABC-02 patients.
cLow score QoL response values versus high-score QoL response values.
dAdjusted for treatment and baseline covariates: gender, disease status, primary tumour site, tumour histology, ECOG performance status, prior therapy, age group.
eMissing data mean that percentages are not 100.
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score). High scores indicate good QoL for functional responses
(e.g. physical functioning), but poor QoL for symptomatic
responses (e.g. pain). The aim of the analysis is to assess whether
having a bad quality of life at baseline is associated with risk of
death, and the results suggest that this is the case for some of the
scales. We reported univariate and multivariate OS cox model
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Figure 1. Quality of life across the five measurable time points for six QoL scales. For each score the mean quality of life is provided with its 95%
confidence interval. (A–F) Represent appetite loss, financial difficulties, constipation, satisfaction with health care, digestive symptoms and hepatic
symptoms, respectively.
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results using 50% cut-offs as suggested by Sloan et al, 2012.
CisGem was compared with Gem in terms of QoL responses at 12
weeks, adjusting for baseline values using ANCOVA (analysis of
covariance), which is used to evaluate QoL at 12 months and is
meaningful as it represents the median survival point.
Random intercept-slope models are fitted in order to take into
account the repeated-measures nature of the QoL data. A separate
model is fitted for each QoL subscale (response variable). These are
two-level models with level 1 being the series of measurements
taken over time within each patient and level 2 being the patient
unit (cluster level). Random intercept-slope models include
treatment group and number of days in each visit for each patient
as fixed-effects covariates. We extended these intercept-slope
models by including baseline characteristics as fixed-effects
covariates: gender, disease status, primary tumour site, tumour
histology, ECOG performance status, prior therapy and age group.
We reported 99% CI for analysis of covariance and random
intercept-slope models due to multiple testing.
RESULTS
Quality of life. A total of 268 (83%) patients returned at least one
QoL form (134 in each arm), though only 259 (80%) returned the
baseline form and 134 (41%) of the patients returned the QoL form
at 12 weeks (Supplementary Table S1). Missing data due to deaths
and due to other causes are similar between treatment groups, with
a slightly higher percentage of missing data due to deaths in the
Gemcitabine arm. Only 11 (3%) patients returned all five forms.
Table 1 shows the association between QoL scores and survival.
A better survival outcome seems to be related with higher score
levels in global health (HR 0.63, 99% CI: 0.44–0.91, P¼ 0.001),
role functioning (HR 0.77, 99% CI: 0.53–1.11, P¼ 0.06), physical
functioning (HR 0.56, 99% CI: 0.34–0.92, P¼ 0.003) and sexual
functioning (HR 0.69, 99% CI: 0.46–1.02, P¼ 0.01) at baseline.
A worst survival experience seem to be associated with higher
baseline score levels in the scales related with appetite loss
(HR 1.42, 99% CI: 0.96–2.10, P¼ 0.02), nausea and vomiting
(HR 1.98, 99% CI: 0.94–4.17, P¼ 0.02), pain (HR 1.50, 99%
CI: 0.94–2.38, P¼ 0.02), digestive symptoms (HR 1.42, 99% CI:
0.90–2.25, P¼ 0.05) and pancreatic pain (HR 1.39, 99% CI:
0.90–2.15, P¼ 0.05). Supplementary Figure S1A and B show
Kaplan–Meier plots for survival outcomes amongst patients who
scored high and low in the global health functioning and physical
functioning scales, respectively.
Treatment mean differences in the QoL scales at 12 weeks
adjusted for baseline (ANCOVA analysis) are presented in Figure 1
and Table 2. The ANCOVA results imply a difference not
statistically significant in the direction favouring the combined
treatment arm for most of the scales. After controlling for baseline
quality of life and baseline characteristics, only appetite loss and
Table 2. Treatment difference in quality of life at 12weeks, adjusting for quality of life at baseline (analysis of covariance)
Models adjusting for
baseline quality of life
Models adjusting for baseline quality of life
and baseline characteristicsa
QoL responseb
Treatment mean differencec
in quality of life at
12 weeksd (99% CI) P-valuee
Treatment mean differencec
in quality of life at
12weeksd (99% CI) P-valuee
Global health status
Global health 6.9 (2.5 to þ16.3) 0.06 5.9 (4.0 to þ15.8) 0.12
Functional scale
Social functioning 9.6 (2.2 to þ21.4) 0.04 8.3 (4.0 to þ20.6) 0.08
Emotional functioning 3.3 (6.5 to þ13.2) 0.38 2.3 (8.0 to þ12.7) 0.56
Cognitive functioning 2.4 (5.9 to þ10.7) 0.45 2.8 (5.8 to þ11.3) 0.40
Role functioning  0.2 (11.4 to þ11.0) 0.96 0.8 (10.8 to þ12.4) 0.86
Physical functioning  0.4 (7.9 to þ7.1) 0.88 1.1 (9.0 to þ6.8) 0.73
Symptom scale
Appetite loss  15.7 (27.8 to 3.5) 0.001 13.2 (25.8 to 0.55) 0.007
Financial difficulties  11.6 (24.6 to þ1.3) 0.02 11.7 (25.0 to þ1.5) 0.02
Nausea and vomiting  5.4 (13.2 to þ2.4) 0.07 3.0 (10.8 to þ4.7) 0.31
Pain  4.8 (15.2 to þ5.6) 0.23 3.7 (14.5 to þ7.1) 0.37
Insomnia  4.5 (16.4 to þ7.4) 0.33 4.9 (17.4 to þ7.7) 0.31
Fatigue  3.9 (14.0 to þ6.3) 0.32 3.5 (14.2 to þ7.3) 0.40
Constipation  1.1 (13.2 to þ11.0) 0.81 0.37 (11.9 to þ12.7) 0.94
Diarrhoea  0.2 (9.6 to þ9.2) 0.95 0.02 (9.8 to þ9.8) 0.99
Dyspnoea 4.8 (6.6 to þ16.2) 0.27 5.2 (6.7 to þ17.1) 0.25
Biliary tract cancer-specific
Satisfaction with health care 12.1 (0.2 to þ24.5) 0.01 11.1 (1.6 to þ23.8) 0.02
Sexual functioning  4.7 (22.0 to þ12.6) 0.48 7.2 (25.5 to þ11.0) 0.30
Digestive symptoms  14.1 (25.7 to 2.5) 0.002 13.4 (25.7 to 0.98) 0.006
Hepatic  5.6 (12.1 to þ0.9) 0.03 5.3 (12.1 to þ1.5) 0.04
Pancreatic pain  3.9 (12.1 to þ4.3) 0.22 3.5 (12.0 to þ4.9) 0.28
Body image  3.6 (15.8 to þ8.7) 0.45 2.0 (14.7 to þ10.8) 0.69
Altered bowel habit  0.7 (11.0 to þ9.6) 0.86 1.7 (12.6 to þ9.3) 0.69
aModels adjusted for baseline characteristics: gender, disease status, primary tumour site, tumour histology, ECOG performance status, prior therapy and age group.
bScores range from 0–100 for all endpoints. For the global health and functional scales (including satisfaction with health care and sexual functioning) 0 indicates poor health and 100 good
health. For all other scales, 0 indicates no symptoms and 100 high level of symptoms.
cTreatment mean difference refers to gemcitabineþ cisplatin minus gemcitabine alone.
dFor the global health and functional scales (including satisfaction with health care and sexual functioning) a positive difference indicates that gemcitabineþ cisplatin was better and a negative
difference indicates that gemcitabine alone was better. For all other scales, a negative difference indicates that gemcitabineþ cisplatin was better and a positive difference indicates that
gemcitabine alone was better.
eP-values (two-sided) are unadjusted for multiple comparisons, so 99% CIs are shown.
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digestive symptoms were statistically significant at the 1% level
(P¼ 0.007 and P¼ 0.006, respectively; Figures 1A andB), both in
favour of CisGem. Our findings suggest some evidence of
treatment differences in favour of CisGem in hepatic function,
financial difficulties and satisfaction with health-care scales
(Figure 1C, E and F).
There is no evidence of a treatment effect in the difference in
mean QoL scores, over all five time points, for any of the QoL
responses at the 1% level (Supplementary Table S2). Responses in
the constipation scale showed a difference in the direction
favouring the combined treatment arm at a 5% level ( 6.3, 99%
CI:  13.5–0.9, P¼ 0.02). A difference favouring the CisGem arm
was seen in digestive symptoms, global health, social functioning,
appetite loss, financial difficulties, insomnia and satisfaction with
health-care scales, but our findings do not suggest evidence of a
statistical difference (Figure 1D and B).
Long-term survivors. Survival analysis and analysis of baseline
characteristics and treatment of patients by grouped length of
follow-up is shown in Table 3. A total of 69 (17%) patients have
been followed up forp3 months, 296 (72%) patients between 3–24
months and 45 (11%) patients for 424 months. Median survival
among the 45 long-term survivors is 31.4 months. There is a trend
between the following factors and survival time: CisGem treatment,
disease status and ECOG performance status (Po0.001, P¼ 0.028
and Po0.001, respectively). There is a survival advantage for
patients receiving CisGem compared with Gem (HR: 0.65, 95% CI:
0.53–0.79, Po0.001), with 17% of the CisGem patients being
followed up for at least 24 months in comparison with 5% of
Gemcitabine-alone patients. Our findings suggest that the higher
the ECOG performance status the poorer the survival, and that a
performance status of 2 is associated with worst prognosis (ECOG
2, HR: 2.35, 95% CI: 1.68–3.28, Po0.001). Locally advanced
patients have a better survival prognosis than the patients with
metastatic disease (HR 1.34, 95% CI: 1.07–1.69, P¼ 0.01). A higher
percentage of locally advanced patients were followed up for 424
months compared with metastatic disease (14% vs 10%, respec-
tively). Our findings did not show evidence that gender, primary
tumour site, tumour histology, prior therapy and age were
associated with survival.
Long-term primary outcome analysis. With a median follow-up
of 9.2 months, 398 (97%) patients have died as of March 2012
compared to 327 when previously reported (Valle et al, 2010). Of
the 12 patients not known to have died, 9 have been followed up
for at least 24 months; the other 3 patients were all lost to follow-
up within 6 months of randomisation. As nearly all the patients
have died, long-term follow-up can be considered as long-term
survival. The median OS was 11.7 months for CisGem and 8.1
months for Gem (HR¼ 0.65, 95% CI: 0.53–0.79, Po0.001,
Figure 2).
Table 3. Baseline characteristics and treatment of patients, by grouped length of follow-up
Univariate cox model Follow-up perioda
Median
survival
time (95% CI)
HR
(95% CI) P-value
0–3 months
(N¼69) n (%)
3–24 months
(N¼296) n (%)
424 months
(N¼45) n (%)
P-valueb
(P-value
for trendc)
Treatment
Gemcitabine alone 8.1 (7.0–9.1) 1 o0.001 43 (21) 152 (74) 11 (5) o0.001GemcitabineþCisplatin 11.7 (9.6–14.0) 0.65 (0.53–0.79) 26 (13) 144 (71) 34 (17) (o0.001)
Gender
Female 9.6 (8.3–11.1) 1
0.38
35 (16) 155 (72) 26 (12) 0.75
Male 9.1 (7.9–11.7) 1.09 (0.90–1.33) 34 (18) 141 (73) 19 (10) 0.5
Disease status
Locally advanced disease 13.3 (8.1–15.0) 1
0.01
11 (11) 78 (75) 15 (14) 0.086
Metastatic disease 8.8 (8.1–10.0) 1.34 (1.07–1.69) 58 (19) 218 (71) 30 (10) 0.028
Primary tumour site
Gallbladder 9.6 (8–11.7) 1 19 (13) 115 (77) 15 (10) 0.053
Bile duct 8.8 (8–10.7) 0.96 (0.78–1.19) 0.93 50 (21) 163 (68) 28 (12) 0.78
Ampulla 11.8 (6.8–14) 1 (0.62–1.62) 0 (0) 18 (90) 2 (10)
Tumour histology
Adenocarcinoma 9.6 (8.3–11.1) 1 0.21 61 (16) 273 (72) 43 (11) 0.37
Other 7.2 (4.5–10.8) 1.27 (0.88–1.82) 8 (24) 23 (70) 2 (6) 0.16
ECOG performance status
0 11.9 (9.7–14.3) 1 11 (8) 98 (75) 21 (16) 0.001
1 9.3 (7.9–11) 1.29 (1.04–1.61) o0.001 42 (18) 163 (71) 23 (10) (o0.001)
2 5.7 (3.4–7.1) 2.35 (1.68–3.28) 16 (31) 35 (67) 1 (2)
Prior therapy
None 8.0 (6.8–10.1) 1 0.79 20 (20) 66 (66) 14 (14) 0.27
Any prior therapy 9.8 (8.7–11.6) 1.03 (0.82–1.30) 49 (16) 230 (74) 31 (10) 0.94
Age (years)
23–60 9.3 (8–12.2) 1 22 (15) 111 (75) 15 (10) 0.23
60–70 9.7 (7.9–11.8) 1 (0.80–1.25) 0.61 32 (18) 118 (67) 25 (14) 0.41
70–84 9.1 (7–10.7) 1.13 (0.86–1.48) 15 (17) 67 (77) 5 (6)
aFollow-up time is near enough an exact proxy for survival. Yet, there are 12 patients who did not die. So, although the FUP time and survival time are almost the same they are not exactly the
same. That is the reason that we use follow-up time instead survival time.
bNote that there are two P-values. The first is for any difference between follow-up duration and covariate groupings; the second is for trend.
cA non-parametric test for linear trend developed by Cuzick (1985) has been calculated to assess if the covariates are associated with follow-up time.
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DISCUSSION
Although ABC-02 has defined the standard of care for BTC
patients, the survival benefit is modest and most patients do not
survive beyond a year. QoL is therefore pivotal to globally evaluate
this benefit, particularly in the context of a disease with multiple
symptoms that can often be difficult to manage. Our data
demonstrate that QoL is not adversely affected despite a modest
non-significant increase in some toxicities such as neutropenia.
Research on QoL in ABC is challenging. Assessing the QoL of
ABC patients is critically important in a population who are often
unwell from both local (obstructive jaundice, biliary sepsis, bowel
obstruction and liver pain) and systemic consequences (malaise,
fatigue and depression) of advanced disease. This is the likely
reason for missing data (20% at baseline and 59% at 12 weeks)
reflecting a common problem of QoL studies in unwell cancer
patients. Extant data reflect both a lack of appropriate instruments
and study compliance realities. Heffernan et al (2002) described the
FACT-G scale for hepatobiliary malignancies, but to date it has
been used only in pancreas cancer studies with no survival benefit
(Rocha Lima et al, 2004; Moinpour et al, 2010). EORTC QoL scales
have been described for liver metastasis (LMC21) (Kavadas et al,
2003) and pancreas (PAN26) (Fitzsimmons et al, 1999), the latter
used here, but are limited by not being BTC specific. It is likely that
a recently validated BTC instrument will be used for BTC in the
future (EORTC QLQ-BIL21; Friend et al, 2011). This is a mostly a
combination of PAN26 and LMC21 and requires phase 4
evaluation across multiple ethnic groups before general adoption.
Limitations of our data include the missing data (Table 1;
Supplementary Table S1) and the assumption that that these data
are balanced between the treatment arms. Nevertheless, these are
the only data describing QoL in the context of a treatment-defining
study for ABC and as such set the standard for subsequent
investigation.
The majority of long-term outcomes are described in surgical
series and there are no published data for the long-term survival of
patients presenting with advanced disease. These data describe a
cohort of long-term survivors and are consistent with an increasing
appreciation that ABC are sensitive to chemotherapy (Eckel et al,
2011). Ongoing studies in second and subsequent line therapies
will continue to build a therapeutic hierarchy for ABC, such as the
UK National Cancer Research Institute ABC-06 study (Lamarca
et al, 2014). The added efficacy of Cisplatin to gemcitabine across
multiple variables including primary tumour site (bile duct, gall
bladder and ampulla) is confirmed, suggesting that although they
may be molecularly heterogeneous (Jiao et al, 2013) their
sensitivity to cisplatin is similar.
CONCLUSION
The survival benefit of CisGem compared to Gem in ABC is not
paralleled by a benefit in QoL. A qualitative description of long-
term survivors and the long-term primary outcome analysis
supports the survival benefit. We recommend that CisGem
remains the standard of care for ABC.
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Figure 2. Kaplan–Meier long-term overall survival by treatment arm.
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